Background. There are already many effective topical therapies available fo
r use in the treatment of chronic plaque psoriasis. Unfortunately, these tr
eatments are often associated with a rather significant risk of undesirable
effects. Objective and Methods: In this randomized, prospective clinical t
rial, the effects of the vitamin D-3 analog calcipotriol were evaluated aga
inst those of a recently developed vitamin B-12 cream containing avocado oi
l in an intraindividual right/left-side comparison. The trial population co
nsisted of 13 patients, 10 men and 3 women, with chronic plaque psoriasis.
The observation period was 12 weeks; the effects of therapy were assessed o
n the basis of a PASI score adapted to the right/left-side comparison techn
ique, the subjective evaluations of the investigator and patients and the r
esults of 20-MHz sonography. Results:There was a more rapid development of
beneficial effects with the use of calcipotriol in the initial 8 weeks, alt
hough differences in effects were significant only at the time point of the
rapy week 8 (p<0.05). After 12 weeks, neither the PASI score nor 20-MHz son
ography showed significant differences between the two treatments. While th
e efficacy of the calcipotriol preparation reached a maximum in the first 4
weeks and then began to subside, the effects of the vitamin B-12 cream con
taining avocado oil remained at a constant level over the whole observation
period. This would indicate that the vitamin B-12 preparation containing a
vocado oil may be suitable for use in long-term therapy, a hypothesis furth
er supported by the fact that the investigator and the patients assessed th
e tolerability of the vitamin B-12 cream containing avocado oil as signific
antly better in comparison with that of calcipotriol. Conclusion: The resul
ts of this clinical trial provide evidence that the recently developed vita
min B-12 cream containing avocado oil has considerable potential as a well-
tolerated, long-term topical therapy of psoriasis. Copyright (C) 2001 S. Ka
rger AG, Basel.